veverimer: Clinical Trials

5 trials of veverimer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 recruiting, 1 terminated. 4 Phase 3, 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 34Completed 2, Recruiting 1, Terminated 1
Phase 11Completed 1
Phase 21Completed 1

Follow veverimer: new trials by email Literature Review of veverimer trials Research Report on veverimer

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis
Veverimer, Placebo - CKD, Metabolic Acidosis
Phase 3RecruitingRenibus Therapeutics, Inc.1502026-01-132026-10-23
Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis
TRC101, Placebo - Metabolic Acidosis, Chronic Kidney Disease
Phase 3TerminatedTricida, Inc.14802018-11-202022-10-14
Long-term Safety Extension to Study TRCA-301
TRC101, Placebo - Metabolic Acidosis
Phase 3CompletedTricida, Inc.1962017-12-202021-10-22
Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease
TRC101, Placebo - Metabolic Acidosis
Phase 3CompletedTricida, Inc.2172017-09-262021-04-26
Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Placebo, TRC101 - Acidosis
Phase 1 / Phase 2CompletedTricida, Inc.1352016-03-012020-01-14

Conditions studied

Acidosis (5)  ·  Kidney Diseases (3)  ·  Renal Insufficiency, Chronic (1)

Sponsors

Tricida, Inc. (4)  ·  Renibus Therapeutics, Inc. (1)

Countries

Bulgaria (4)  ·  Georgia (4)  ·  United States (4)  ·  Hungary (3)  ·  Serbia (3)  ·  Ukraine (3)  ·  Slovenia (2)  ·  Albania (1)  ·  Argentina (1)  ·  Armenia (1)  ·  Australia (1)  ·  Belarus (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Canada (1)

Top investigators

Yuri Stasiv, PhD (1)

Results publications

PMID 29102959, PMID 30857647, PMID 31248662, PMID 34009141, PMID 35216581, PMID 38261535

NIH funding

2015 (1), 2016 (1), 2018 (1)